title: Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias.
abstract: Osteonecrosis of the jaw has been linked with bisphosphonate use in breast cancer and multiple myeloma patients. We report 17 cases of patients with plasma cell dyscrasia being treated with bisphosphonate who developed osteonecrosis/osteomyelitis of the jaw. Seventeen patients evaluated at our institution between 1998 and 2005 are reported. All were being treated with bisphosphonates for a median of 5 mo prior to the onset of jaw symptoms. Sixteen of the 17 patients are 51 yr or older. None of the patients had been irradiated in the jaw nor had obvious osseous manifestation of multiple myeloma in the jaw. Thirteen patients were receiving zoledronic acid and four patients were receiving pamidronate at the onset of jaw symptoms. Six of the 17 did receive both agents at some time and all of these individuals were receiving zoledronic acid at diagnosis. Microorganisms were isolated in 7/17 patients with the most common organism being actinomycosis. We have initiated the following guidelines in an effort to ameliorate the incidence of this complication. Patients should have a full dental examination at the time of diagnosis of the plasma cell dyscrasia especially if bisphosphonates are to be considered as part of the therapy. In addition, bisphosphonates are held for a period of 3 mo prior to invasive dental procedures to allow for the osteoclastic recovery, therefore enhanced debris removal and lessening the chance of creating a fertile bacterial medium. Following the dental procedure we would re-introduce bisphosphonates only after the healing process is complete. Finally, multiple myeloma patients diagnosed with jaw osteonecrosis probably have a concurrent infection and should be aggressively treated with antibiotics.
authors.affiliation: Multiple Myeloma Multidisciplinary Clinical Research Program-R35, Cleveland Clinic Foundation 9500 Euclid Avenue, OH 44195, USA.thakkas@ccf.org
authors.forename: S G
authors.initials: SG
authors.lastname: Thakkar
authors.forename: C
authors.initials: C
authors.lastname: Isada
authors.forename: J
authors.initials: J
authors.lastname: Smith
authors.forename: M A
authors.initials: MA
authors.lastname: Karam
authors.forename: J
authors.initials: J
authors.lastname: Reed
authors.forename: J W
authors.initials: JW
authors.lastname: Tomford
authors.forename: K
authors.initials: K
authors.lastname: Englund
authors.forename: M
authors.initials: M
authors.lastname: Richmond
authors.forename: A
authors.initials: A
authors.lastname: Licata
authors.forename: C
authors.initials: C
authors.lastname: Hatch
authors.forename: M A
authors.initials: MA
authors.lastname: Hussein
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004164:Diphosphonates / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects; D007571:Jaw Diseases / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D010019:Osteomyelitis / Q000139:chemically induced; D010020:Osteonecrosis / Q000139:chemically induced*; D000077268:Pamidronate; D010265:Paraproteinemias / Q000188:drug therapy*; D000077211:Zoledronic Acid
chemical_list: D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D000077268:Pamidronate